Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug;6(4):100235.
doi: 10.1016/j.esmoop.2021.100235. Epub 2021 Aug 7.

Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge

M Bono  1 , D Fanale  1 , L Incorvaia  2 , D Cancelliere  1 , A Fiorino  1 , V Calò  1 , A Dimino  1 , C Filorizzo  1 , L R Corsini  1 , C Brando  1 , G Madonia  1 , A Cucinella  1 , R Scalia  1 , N Barraco  1 , F Guadagni  3 , E Pedone  1 , G Badalamenti  1 , A Russo  4 , V Bazan  2
Affiliations

Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge

M Bono et al. ESMO Open. 2021 Aug.

Abstract

Background: Hereditary breast cancer (BC), ovarian cancer (OC), and pancreatic cancer (PC) are the major BRCA-associated tumours. However, some BRCA1/2-wild-type (wt) patients with a strong personal and/or family history of cancer need a further genetic testing through a multi-gene panel containing other high- and moderate-risk susceptibility genes.

Patients and methods: Our study was aimed to assess if some BC, OC, or PC patients should be offered multi-gene panel testing, based on well-defined criteria concerning their personal and/or family history of cancer, such as earliness of cancer onset, occurrence of multiple tumours, or presence of at least two or more affected first-degree relatives. For this purpose, 205 out of 915 BC, OC, or PC patients, resulted negative for BRCA1/2 and with significant personal and/or family history of cancer, were genetically tested for germline pathogenic or likely pathogenic variants (PVs/LPVs) in genes different from BRCA1/2.

Results: Our investigation revealed that 31 (15.1%) out of 205 patients harboured germline PVs/LPVs in no-BRCA genes, including PALB2, CHEK2, ATM, MUTYH, MSH2, and RAD51C. Interestingly, in the absence of an analysis conducted through multi-gene panel, a considerable percentage (15.1%) of PVs/LPVs would have been lost.

Conclusions: Providing a multi-gene panel testing to BRCA1/2-wt BC/OC/PC patients with a strong personal and/or family history of cancer could significantly increase the detection rates of germline PVs/LPVs in other cancer predisposition genes beyond BRCA1/2. The use of a multi-gene panel testing could improve the inherited cancer risk estimation and clinical management of patients and unaffected family members.

Keywords: breast cancer; germline pathogenic variants; multi-gene panel testing; ovarian cancer; pancreatic cancer.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors have declared no conflicts of interest.

Figures

Figure 1
Figure 1
Distribution of PVs/LPVs detected in 31 BC, OC, or PC patients analysed with multi-gene panel testing. The OncoPrint, showing the identified PVs/LPVs by heatmap, was obtained by the informatics tool Mutation Mapper (cBioPortal for Cancer Genomics). The intronic variant sequences (IVS) are not shown. BC, breast cancer; LPV, likely pathogenic variant; OC, ovarian cancer; PC, pancreatic cancer; PV, pathogenic variant.
Figure 2
Figure 2
Percentage distribution of no-BRCA genes altered in BC, OC, or PC patients detected by multi-gene panel testing. BC, breast cancer; OC, ovarian cancer; PC, pancreatic cancer.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. El Ansari F.Z., Jouali F., Marchoudi N. Screening of BRCA1/2 genes mutations and copy number variations in patients with high risk for hereditary breast and ovarian cancer syndrome (HBOC) BMC Cancer. 2020;20(1):747. - PMC - PubMed
    1. Incorvaia L., Fanale D., Badalamenti G. Hereditary breast and ovarian cancer in families from Southern Italy (Sicily)—prevalence and geographic distribution of pathogenic variants in BRCA1/2 genes. Cancers. 2020;12(5):1158. - PMC - PubMed
    1. Russo A., Calò V., Bruno L. Is BRCA1-5083del19, identified in breast cancer patients of Sicilian origin, a Calabrian founder mutation? Breast Cancer Res Treat. 2008;113(1):67–70. - PubMed
    1. Pilarski R. The role of BRCA testing in hereditary pancreatic and prostate cancer families. Am Soc Clin Oncol Educ Book. 2019;39:79–86. - PubMed
    1. Mocci E., Milne R.L., Méndez-Villamil E.Y. Risk of pancreatic cancer in breast cancer families from the Breast Cancer Family Registry. Cancer Epidemiol Biomarkers Prev. 2013;22(5):803–811. - PMC - PubMed